These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 9212742)

  • 21. Cyclin D1 (PRAD1) protein expression in breast cancer: approximately one-third of infiltrating mammary carcinomas show overexpression of the cyclin D1 oncogene.
    Zukerberg LR; Yang WI; Gadd M; Thor AD; Koerner FC; Schmidt EV; Arnold A
    Mod Pathol; 1995 Jun; 8(5):560-7. PubMed ID: 7675778
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of cyclin D1 protein expression and gene amplification in invasive breast carcinoma.
    Ortiz AB; Garcia D; Vicente Y; Palka M; Bellas C; Martin P
    PLoS One; 2017; 12(11):e0188068. PubMed ID: 29140993
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclin D1 expression in ductal carcinoma in situ, atypical ductal hyperplasia and usual ductal hyperplasia: an immunohistochemical study.
    Umekita Y; Yoshida H
    Pathol Int; 2000 Jul; 50(7):527-30. PubMed ID: 10886733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis.
    Murphy DS; Hoare SF; Going JJ; Mallon EE; George WD; Kaye SB; Brown R; Black DM; Keith WN
    J Natl Cancer Inst; 1995 Nov; 87(22):1694-704. PubMed ID: 7473818
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin D1 gene expression in human cervical neoplasia.
    Nichols GE; Williams ME; Gaffey MJ; Stoler MH
    Mod Pathol; 1996 Apr; 9(4):418-25. PubMed ID: 8729983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression profiling of ductal carcinomas in situ and invasive breast tumors.
    Seth A; Kitching R; Landberg G; Xu J; Zubovits J; Burger AM
    Anticancer Res; 2003; 23(3A):2043-51. PubMed ID: 12894577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining.
    Gillett C; Fantl V; Smith R; Fisher C; Bartek J; Dickson C; Barnes D; Peters G
    Cancer Res; 1994 Apr; 54(7):1812-7. PubMed ID: 8137296
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion.
    Asch HL; Winston JS; Edge SB; Stomper PC; Asch BB
    Breast Cancer Res Treat; 1999 May; 55(2):179-88. PubMed ID: 10481945
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High CCND1 amplification identifies a group of poor prognosis women with estrogen receptor positive breast cancer.
    Roy PG; Pratt N; Purdie CA; Baker L; Ashfield A; Quinlan P; Thompson AM
    Int J Cancer; 2010 Jul; 127(2):355-60. PubMed ID: 19904758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma.
    Zhang YJ; Jiang W; Chen CJ; Lee CS; Kahn SM; Santella RM; Weinstein IB
    Biochem Biophys Res Commun; 1993 Oct; 196(2):1010-6. PubMed ID: 8240318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic progression, histological grade, and allelic loss in ductal carcinoma in situ of the breast.
    Fujii H; Szumel R; Marsh C; Zhou W; Gabrielson E
    Cancer Res; 1996 Nov; 56(22):5260-5. PubMed ID: 8912866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gene amplification of CCNE1, CCND1, and CDK6 in gastric cancers detected by multiplex ligation-dependent probe amplification and fluorescence in situ hybridization.
    Ooi A; Oyama T; Nakamura R; Tajiri R; Ikeda H; Fushida S; Dobashi Y
    Hum Pathol; 2017 Mar; 61():58-67. PubMed ID: 27864121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cyclin-D1-gene amplification and expression in breast carcinoma: relation with clinicopathologic characteristics and with retinoblastoma gene product, p53 and p21WAF1 immunohistochemical expression.
    Barbareschi M; Pelosio P; Caffo O; Buttitta F; Pellegrini S; Barbazza R; Dalla Palma P; Bevilacqua G; Marchetti A
    Int J Cancer; 1997 Apr; 74(2):171-4. PubMed ID: 9133450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amplification units and translocation at chromosome 17q and c-erbB-2 overexpression in the pathogenesis of breast cancer.
    Coene ED; Schelfhout V; Winkler RA; Schelfhout AM; Van Roy N; Grooteclaes M; Speleman F; De Potter CR
    Virchows Arch; 1997 May; 430(5):365-72. PubMed ID: 9174626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclin D1 (PRAD1, CCND1) and glutathione-S-transferase pi gene expression in head and neck squamous cell carcinoma.
    Gaffey MJ; Iezzoni JC; Meredith SD; Boyd JC; Stoler MH; Weiss LM; Zukerberg LR; Levine PA; Arnold A; Williams ME
    Hum Pathol; 1995 Nov; 26(11):1221-6. PubMed ID: 7590696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma.
    Jang M; Kim E; Choi Y; Lee H; Kim Y; Kim J; Kang E; Kim SW; Kim I; Park S
    Breast Cancer Res; 2012 Aug; 14(4):R115. PubMed ID: 22863309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome.
    Elsheikh S; Green AR; Aleskandarany MA; Grainge M; Paish CE; Lambros MB; Reis-Filho JS; Ellis IO
    Breast Cancer Res Treat; 2008 May; 109(2):325-35. PubMed ID: 17653856
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paget's disease of the nipple: a copy number of the genes ERBB2 and CCND1 versus expression of the proteins ERBB-2 and cyclin D1.
    Mrhalova M; Kodet R
    Neoplasma; 2003; 50(6):396-402. PubMed ID: 14689059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. S100A7 (psoriasin) expression is associated with aggressive features and alteration of Jab1 in ductal carcinoma in situ of the breast.
    Emberley ED; Alowami S; Snell L; Murphy LC; Watson PH
    Breast Cancer Res; 2004; 6(4):R308-15. PubMed ID: 15217497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
    Park K; Han S; Kim HJ; Kim J; Shin E
    Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.